Pharmeasy IPO (API Holdings IPO)

#pharmeasy #apiholdings #pharmeasyipo

A thread on the key takeaways from DHRP .....

IPO expected in Feb 2021

investmentbank.kotak.com/downloads/api-… Image
The parent company of PharmEasy, API Holdings, has filed for its DRHP with SEBI on 08th Nov for a fresh issue of ₹6,250cr ($830m) value equity shares and there is no offer for sale (OFS) by the promoters.

They are also looking for a pre-IPO placement of ₹1,250 cr in this issue
Objectives of the issue
1. Repay its outstanding debt of ₹1,930cr
2. Fund organic growth initiatives ₹1,260cr (marketing and promotional activities, supply chain and ramp up technology infra)
3. Fund inorganic growth initiatives ₹1,500cr
4. Corporate purposes ₹1,560cr
Banks involved
# Kotak Mahindra
# Morgan Stanley India
# BofA Securities India
# Citigroup Global Markets India
# JM Financial
PharmEasy not just takes online orders of medicines but also offers teleconsultation, diagnostic tests & s/w services

Co-founders Siddharth, Dhaval, Dhramil, Harsh and Hardik started their journey with on-call telecon platform DialHealth in 2012, which evolved into PharmEasy
Over the last two years, the firm has made five acquisitions
- Ascent Healthcare
- Thyrocare
- Akna Medical
- Marg ERP
- Medlife

These have helped it become largest online aggregator and increase its scale in technology, Pharma distribution and Diagnostics
The increase of scale due to acquisitions is evident in the operating revenue which went up 3.5X to ₹2,335cr in FY21 from ₹667cr in FY20.

PharmEasy also benefited from the sale of medicines from its online platform during the Covid-induced lockdowns. Image
Key Numbers DHRP

# GMV ₹78.65 billion
# Revenue ₹43.2 billion
# Active Pharmacies 87,194
# Active wholesalers 3,261
# Prescribing doctors 4,617
# E-consultations 3.4 million
# Digital prescriptions generated 10.7 million
# Registered users on PharmEasy 2.5 crore Image
Naspers Ventures BV and Temasek are the largest shareholders in the company with ~12% percent and ~11% percent stakes.

While CEO Siddharth Shah has less then 2% of the shareholding Image
In Oct'2021, it raised ₹2,600cr ($350m) in pre-IPO round from Amansa Capital, hedge fund Janus Henderson and other investors

The round valued API Holdings at $5.4bn at a revenue multiple of 17X.

It was valued at $4bn after it acquired diagnostics chain Thyrocare for over $600m
API Holdings has a $100 Billion market opportunity

India’s digital penetration in health is at a nascent stage
- Online pharmacy at 2.3%
- Doctor consultation via online platforms at 0.8%

and is considerably lower than China (10-15%) and US (30-35%) Image
API Holdings generates revenue from four segments:

1. Product to retailers ₹966cr
2. Products to institutions / chemists ₹1,315cr (56% - was non-existent during FY20)
3. Sale Of Services ₹26cr
4. Other Operating Revenue ₹28cr

GMV rose by 54% to ₹7,865cr by FY21. Image
# Annual costs surged 2.8X in FY21
# It spent ₹1.27 to earn a ₹1 of rev, improving by 22% from ₹1.62 in FY20
# Cost of procuring grew 3.4X in line with revenues / GMV
# Employee expense grew by 1.97X reflecting acquisitions
# Sales promotion & marketing expenses remained flat Image
# burned more cash during FY21 as annual losses spiked by 91.3% to ₹641cr in FY21 from ₹335cr in FY20

# however EBITDA margin improved from nearly -43% in FY20 to -23% in FY21 even after increasing its operating scale >3X

# Thyrocare earnings not incl in FY21 numbers Image
Keys risks

# Healthcare industry in India is subject to extensive government regulation and supervision

# Faces intense competition from other online platforms, wholesalers and diagnostics companies

# Changing regulations could lead to new compliance requirements in ecommerce
Conclusions #1

# Few generic concerns which could be addressed

# “PharmEasy” brand has traction + PharmEasy is India’s top healthcare super app

# although loss making they are growing rapidly with improving bottomline

# Massive unpenetrated TAM and they are market leaders
Conclusions #2

# With few comparable listed peers makes it difficult to Value. The market has stumped people with the high valuations given to both Zomato and Nykaa, even with aggressive pricing

# It will all come down to the premium it seeks for the digital platform
Many thanks and glad you retweeted for helping people understand what they are buying into
Many thanks and glad you retweeted for helping people understand what they are buying into

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Mohit Agarwal12

Mohit Agarwal12 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @agrawalmohit12

28 Nov
I write a thread every now and then

Here are all of them, chronologically
Pharmeasy IPO (API Holdings IPO) - currently (Nov 2021) unlisted in India

Read 6 tweets
26 Nov
Indian Energy Exchange (iexindia.com), a marketplace that provides nationwide automated & transparent trading platform for the physical delivery of electricity, renewables and certificates.

Publicly listed company with NSE: IEX and BSE: 540750 since Oct'17 @iexindia Image
Commenced operations in 2008; CERC regulated
Current Price : ₹776 (~400% above the IPO price)
52 WH – 52 WL : ₹ 956 / ₹199
Market Cap : ₹ 23,261 Cr.
Enterprise Value : ₹ 23,105 Cr.
P/E : 88
Div Yield : 0.17 %
ROCE : 59.7 %
Debt to equity : 0.02
Sales growth 3Yrs : 11.2 % Image
Energy Sector in India is rapidly transforming underpinned by
1. Decarbonization (50% RE capacity by 2030)
2. Decentralization (move from centralized generation to distributed)
3. Democratization (giving customer the economic choice)
4. Digitization (use of tech to optimize) Image
Read 27 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Thank you for your support!

Follow Us on Twitter!

:(